Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tryp Therapeutics Inc (CSE: TRYP )

0.0550 UNCHANGED
Streaming Delayed Price Updated: 12:05 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0550
Bid (Size) 0.0500 (168,000)
Ask (Size) 0.0650 (20,000)
Prev. Close 0.0550
Today's Range 0.0550 - 0.0550
52wk Range 0.0100 - 0.1100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Shareholders Approve Arrangement Agreement at Annual General and Special Meeting
Via Investor Brand Network
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
Via ACCESSWIRE

Performance

YTD
+10.00%
+10.00%
1 Month
+120.00%
+120.00%
3 Month
+37.50%
+37.50%
6 Month
-8.33%
-8.33%
1 Year
-45.00%
-45.00%

More News

Read More
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Interim Order from BC Supreme Court, Plans Meeting of Securityholders
Via Investor Brand Network
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Exopharm Limited Secure Approval from ASX for ‘Pivotal’ Two-Cent Waiver
Via Investor Brand Network
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) TRP-8803 Clinical Trial Reaches ‘Significant Milestone’
Via Investor Brand Network
Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Dosing of First Patient in Phase 2a TRP-8802 Clinical Trial
Via Investor Brand Network
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Inks Definitive Agreement with Exopharm Limited
Via Investor Brand Network
Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Closing of Oversubscribed Private Placement
Via Investor Brand Network
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Anticipates Gross Proceeds of AUD$3M on Private Placement
Via Investor Brand Network
Exposures Product Safety
Tryp Therapeutics Inc. Announces Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3.0 Million
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Closes on AUD$175,000 Private Placement
Via Investor Brand Network
Exposures Product Safety
Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Life Sciences Exec as New CEO
Via Investor Brand Network
Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Reports on the Passing of Director David Tousley
Via Investor Brand Network
With Great Sadness Tryp Announces the Passing of David Tousley, Director
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Proceed with Phase 2A Clinical Trial in Patients with IBS
Via Investor Brand Network
Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND as Important Step in Advancing IBS Clinical Program
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.